| Dr Christina Koo Speirs, | |
|
2226 Liliha St, B2, Honolulu, HI 96817-1600 | |
| (808) 547-6881 | |
| (808) 547-6583 |
| Full Name | Dr Christina Koo Speirs |
|---|---|
| Gender | Female |
| Speciality | Radiation Oncology |
| Experience | 13 Years |
| Location | 2226 Liliha St, Honolulu, Hawaii |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386934495 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | 18300 (Hawaii) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Queens Medical Center | Honolulu, HI | Hospital |
| Pali Momi Medical Center | Aiea, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cancer Center Of Hawaii Llc | 4981673514 | 7 |
| Gamma Knife Center Of The Pacific Inc | 2668361619 | 4 |
| Pacific Radiation Oncology Llc | 6901881077 | 7 |
News Archive
BHR Pharma, LLC (BHR) announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its proprietary BHR-100 intravenous progesterone infusion product.
For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology.
Using fitness DVDs to work out at home may seem like a good way to get started on new exercise goals this year, but those DVDs may also include negative imagery and demotivating language.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.
› Verified 7 days ago
| Entity Name | Gamma Knife Center Of The Pacific Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184789513 PECOS PAC ID: 2668361619 Enrollment ID: O20040315001186 |
News Archive
BHR Pharma, LLC (BHR) announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its proprietary BHR-100 intravenous progesterone infusion product.
For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology.
Using fitness DVDs to work out at home may seem like a good way to get started on new exercise goals this year, but those DVDs may also include negative imagery and demotivating language.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.
› Verified 7 days ago
| Entity Name | Pacific Radiation Oncology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003851932 PECOS PAC ID: 6901881077 Enrollment ID: O20040622001357 |
News Archive
BHR Pharma, LLC (BHR) announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its proprietary BHR-100 intravenous progesterone infusion product.
For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology.
Using fitness DVDs to work out at home may seem like a good way to get started on new exercise goals this year, but those DVDs may also include negative imagery and demotivating language.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.
› Verified 7 days ago
| Entity Name | Cancer Center Of Hawaii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285746636 PECOS PAC ID: 4981673514 Enrollment ID: O20040929001060 |
News Archive
BHR Pharma, LLC (BHR) announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its proprietary BHR-100 intravenous progesterone infusion product.
For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology.
Using fitness DVDs to work out at home may seem like a good way to get started on new exercise goals this year, but those DVDs may also include negative imagery and demotivating language.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christina Koo Speirs, 2226 Liliha St, B2, Honolulu, HI 96817-1600 Ph: (808) 547-6881 | Dr Christina Koo Speirs, 2226 Liliha St, B2, Honolulu, HI 96817-1600 Ph: (808) 547-6881 |
News Archive
BHR Pharma, LLC (BHR) announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its proprietary BHR-100 intravenous progesterone infusion product.
For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology.
Using fitness DVDs to work out at home may seem like a good way to get started on new exercise goals this year, but those DVDs may also include negative imagery and demotivating language.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.
› Verified 7 days ago
Dr. Samuel M. Wu, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-432-0000 | |
Dr. Horia Vulpe, MD, CM Radiology Medicare: Accepting Medicare Assignments Practice Location: 1301 Punchbowl St, Honolulu, HI 96813 Phone: 808-691-8777 Fax: 808-691-8780 | |
Howard K. Arimoto, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 347 N Kuakini St, Honolulu, HI 96817 Phone: 808-522-0190 Fax: 808-523-9068 | |
Dr. Mark T. Kanemori, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1650 Liliha St, Suite 105, Honolulu, HI 96817 Phone: 808-524-3131 Fax: 808-524-3189 | |
Dr. Ferdinand K Hui, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 550 S Beretania St Ste 405, Honolulu, HI 96813 Phone: 808-691-8866 | |
Dr. Jean Paul Colon-pons, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1380 Lusitana St Ste 1007, Honolulu, HI 96813 Phone: 808-748-4488 Fax: 808-748-4799 | |
Kristen T. Nagata, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-432-0000 |